To include your compound in the COVID-19 Resource Center, submit it here.

In a first for the British Business Bank, firm backs Epidarex’s new fund

£102M raise gives trans-Atlantic firm ability to retain larger stakes later in life sciences portfolio companies

Epidarex’s latest fund will give the trans-Atlantic firm the ability to retain larger stakes later into the life cycle of portfolio companies. The fund also marks the first life sciences cornerstone investment from the British Business Bank, as it steps in for the European Investment Fund in a post-Brexit

Read the full 495 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers